Beobachtungsplan, NIS 772: Prospective non-interventional study (NIS) to examine the effectiveness of Tremelimumab + Durvalumab + platinum chemotherapy (TDC) in patients with metastatic non-squamous NSCLC and high-risk genetic alterations

Datei

• Artikel "Beobachtungsplan, NIS 772: Prospective non-interventional study (NIS) to examine the effectiveness of Tremelimumab + Durvalumab + platinum chemotherapy (TDC) in patients with metastatic non-squamous NSCLC and high-risk genetic alterations"Herunterladen(PDF, 2MB, Datei ist nicht barrierefrei)